Why Buying Beats Building for EAP Management
Introduction
Pharmaceutical companies managing Expanded Access Programs (EAPs) face a critical decision: build a custom solution in-house or buy a purpose-built platform. While in-house development promises control, the reality is steep costs, complexity, and ongoing maintenance. MedaSystems shows why buying is the smarter choice.
1. EAPs Require Specialized Solutions
Much like clinical trials, EAPs demand strict regulatory compliance, real-time collaboration, and secure data management. Developing such a system from scratch is not only unrealistic but also risky. Purpose-built platforms like MedaSystems are designed with these exact needs in mind, ensuring efficiency and compliance from day one
2. Hidden Costs and Delays of In-House Builds
Creating software in-house is not just a matter of hiring a few developers. It involves:
Significant upfront investments in infrastructure and talent.
Lengthy development timelines, stretching into years.
Complex validation requirements, with every update needing re-validation
.
For companies needing fast solutions, these delays can be unacceptable.
3. Resource-Intensive and Risky Maintenance
Launching is only the beginning. In-house systems require:
Continuous monitoring, bug fixes, and upgrades.
Costly adjustments every time regulations evolve.
Ongoing compliance and security oversight.
By contrast, MedaSystems provides automatic updates that keep systems secure, compliant, and up to date
4. MedaSystems Delivers Out-of-the-Box Capabilities
MedaSystems offers built-in features tailored to EAP management, including:
Centralized request tracking and filtering.
Real-time collaboration tools and secure messaging.
Audit trails for compliance (GxP standards like FDA’s 21 CFR Part 11 and EU Annex 11)
AI-powered PHI redaction for patient privacy.
Dashboards, custom form builders, and advanced reporting.
These features allow companies to focus on delivering vital therapies rather than IT headaches.
5. Scalability, Compliance, and Dedicated Support
MedaSystems evolves with changing regulations, offers seamless updates, and eliminates the burden of training external users. With 24/7 support, healthcare providers, regulators, and other stakeholders can easily engage with the system without heavy onboarding requirements.
Conclusion: Buying Isn’t Just Smart—It’s Essential
For pharmaceutical companies, the build vs. buy debate is clear. MedaSystems offers a ready-to-use, compliant, and secure platform that saves time, reduces costs, and delivers life-saving treatments faster.
👉 Check out our white paper, Build vs. Buy, 5 Reasons to Choose MedaSystems Over Building In-House.
